The article below from OncLive, provides a high level overview of trials experience of the new drugs Ibrutinib, Idelalisib and IPI-145 by Jeffrey Jones, MD, from The Ohio State University to the NCCN 8th Annual Congress on Hematologic Malignancies. Brief mention is also made of the benefits observed when using Ibrutinib with Ofatumumab (Arzerra) and rituximab.
Drugs targeting B-cell receptor (BCR) signaling pathways are improving outcomes for patients with B-cell lymphomas, including chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma (NHL), and mantle cell lymphoma (MCL). These novel agents include PI3-Kinase (PI3K) inhibitors (eg, idelalisib) and Bruton’s tyrosine kinase (BTK) inhibitors (eg, ibrutinib), and are considered a breakthrough for CLL and other B-cell lymphomas.
At the recent NCCN 8th Annual Congress on Hematologic Malignancies, Jeffrey Jones, MD, from The Ohio State University Comprehensive Cancer Center and James Cancer Hospital and Solove Research Institute, updated listeners on these two new targeted drug classes:
(This Musk Lorikeet proved challenging to photograph, as it was very actively foraging for nectar and pollen from the bottlebrush shrub.)